Oberland Capital

Day-to-day investment activity is led by Partners Michele Gonzalo and Alexandra Siber from the New York office. Gonzalo joined from Vatera Healthcare Partners and previously worked at Essex Woodlands and Warburg Pincus; Siber's background includes corporate development at Pfizer and Blackstone Alternative Asset Management. The firm's website indicates an investment committee structure, though specific members beyond the named partners are not publicly disclosed.

Oberland relies on a suite of structured, non-dilutive instruments — chiefly royalty monetizations, revenue-interest agreements, and royalty-backed term loans — with traditional equity used only as a complement in hybrid structures. The firm describes a typical transaction as supplying $50 million to $300 million in exchange for rights to future product royalties or revenue streams, often allowing the portfolio company to fund late-stage trials or commercial build-outs without issuing new equity.

Oberland's focus is primarily on commercial-stage and near commercial-stage healthcare products, although the firm states it will consider earlier-stage opportunities in certain cases. The portfolio page reinforces this posture: most publicly announced deals — such as Biohaven, Zealand Pharma, and Humacyte — involve companies with regulatory approvals or late-stage clinical assets.

Oberland operates as a private investment firm, not a single-family office. The firm manages commingled institutional capital and reports approximately $3.2 billion in assets under management, deploying capital on behalf of third-party limited partners. Its public filings and website do not reference any single family wealth source or a family-office charter.

Oberland's model centers on direct, bilateral transactions with healthcare companies — structured royalties, credit facilities, and revenue-interest deals — rather than making commitments to external venture or private-equity funds. The firm's strategy materials do not list fund-of-funds activity, and the public portfolio consists exclusively of company-level investments.

The firm invests across all therapeutic categories and modalities, with publicly disclosed positions in oncology, rare liver disease, neuroscience, retinal disorders, and precision diagnostics. Geographically, Oberland executes transactions in the United States and Europe, with at least two Swiss-based companies — Helsinn and NLS Pharmaceutics — appearing in past portfolio references.

Oberland structures its royalty and debt positions to self-liquidate through contracted product-revenue streams over multi-year periods. In royalty-backed loans, principal and interest are repaid solely from the royalty receipts, and once the loan is satisfied, the royalty rights revert to the original holder. The firm's long-term investment horizon aligns with the clinical and commercial timelines of the underlying healthcare products.